Denali Therapeutics Inc (DNLI) — Cash Flow Quality Index
Denali Therapeutics Inc (DNLI) has a Cash Flow Quality Index of -0.62x as of June 2023. Operating cash flow of $-113.17 Million is below net income of $183.38 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore DNLI operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Denali Therapeutics Inc Cash Flow Quality Index (2020–2020)
Historical Cash Flow Quality Index for Denali Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Denali Therapeutics Inc.
Annual Cash Flow Quality Index for Denali Therapeutics Inc (2020–2020)
Year-by-year earnings quality comparison for Denali Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 5.85x | $416.15 Million | $71.14 Million | — |